4.1 Article

Fumarate hydratase immunohistochemical staining may help to identify patients with multiple cutaneous and uterine leiomyomatosis (MCUL) and hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome

Journal

JOURNAL OF CUTANEOUS PATHOLOGY
Volume 41, Issue 11, Pages 859-865

Publisher

WILEY-BLACKWELL
DOI: 10.1111/cup.12396

Keywords

fumarase; immunocytochemistry; piloleiomyoma

Ask authors/readers for more resources

AimsMultiple cutaneous and uterine leiomyomatosis (MCUL) also named as hereditary leiomyomatosis and renal cancer syndrome (HLRCC) is an autosomal dominant disorder caused by heterozygotic germline mutations in fumarate hydratase (FH) with incomplete penetrance and clinically challenging to diagnose. To test immunohistochemistry for FH as a potential marker for the detection of FH-deficiency. Methods and resultsWe have tested 42 smooth muscle neoplasms, 13 lesions of patients with suspicious or confirmed HLRCC, 20 sporadic piloleiomyomas, two angioleiomyomas and 7 leiomyosarcomas. FH staining grades from 1 to 3. Ten of the 13 lesions from the patients with HLRCC syndrome showed negative FH staining. Most sporadic piloleiomyomas presented grade 3 FH staining although five cases presented grade 1 FH staining. Sensitivity of FH staining in our series is 83.3% but specificity is 75%. ConclusionsThis staining could indicate a high risk of HLRCC in most of the confirmed cases but it could also suggest the presence of a syndrome in up to 25% of sporadic cases. HLRCC syndrome should be rule out in FH negative piloleiomyomas after complete anamnesis if multiple lesions or positive familiar history is found.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Dermatology

Diagnostic performance of artificial intelligence for histologic melanoma recognition compared to 18 international expert pathologists

Titus J. Brinker, Max Schmitt, Eva I. Krieghoff-Henning, Raymond Barnhill, Helmut Beltraminelli, Stephan A. Braun, Richard Carr, Maria-Teresa Fernandez-Figueras, Gerardo Ferrara, Sylvie Fraitag, Raffaele Gianotti, Mar Llamas-Velasco, Cornelia S. L. Mueller, Antonio Perasole, Luis Requena, Omar P. Sangueza, Carlos Santonja, Hans Starz, Esmeralda Vale, Wolfgang Weyers, Achim Hekler, Jakob N. Kather, Stefan Froebling, Dieter Krahl, Tim Holland-Letz, Jochen S. Utikal, Andrea Saggini, Heinz Kutzner

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Article Dermatology

Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases

A. Catala, C. Munoz-Santos, C. Galvan-Casas, M. Roncero Riesco, D. Revilla Nebreda, A. Sola-Truyols, P. Giavedoni, M. Llamas-Velasco, C. Gonzalez-Cruz, X. Cubiro, R. Ruiz-Villaverde, S. Gomez-Armayones, M. P. Gil Mateo, D. Pesque, O. Marcantonio, D. Fernandez-Nieto, J. Romani, N. Iglesias Pena, L. Carnero Gonzalez, J. Tercedor-Sanchez, G. Carretero, T. Masat-Tico, P. Rodriguez-Jimenez, A. M. Gimenez-Arnau, M. Utrera-Busquets, E. Vargas Laguna, A. G. Angulo Menendez, E. San Juan Lasser, M. Iglesias-Sancho, L. Alonso Naranjo, I Hiltun, E. Cutillas Marco, I Polimon Olabarrieta, S. Marinero Escobedo, X. Garcia-Navarro, M. J. Calderon Gutierrez, G. Baeza-Hernandez, L. Bou Camps, T. Toledo-Pastrana, A. Guilabert

Summary: This study investigated cutaneous reactions after SARS-CoV-2 vaccination, finding that most were mild to moderate, but severe cases were also reported. Understanding these reactions can help healthcare professionals and reassure patients.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Article Dermatology

Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents

Raquel Navarro, Yolanda Delgado-Jimenez, Juan Guinea-Viniegra, Mar Llamas-Velasco, Esteban Dauden

Summary: The study found that the expression profiles of miR-21 and TIMP-3 differ between induced psoriasis and non-induced psoriasis, with most cases of paradoxical psoriasiform reactions showing high TIMP-3 expression, while the control group showing different patterns. This suggests that various pro-inflammatory cytokines are involved in the pathogenesis of paradoxical psoriasiform reactions and non-induced psoriasis.

JOURNAL OF CUTANEOUS PATHOLOGY (2022)

Article Dermatology

Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Elena del Alcazar, Anna Lopez-Ferrer, Alvaro Martinez-Domenech, Ricardo Ruiz-Villaverde, Ma. del Mar Llamas-Velasco, Vicenc Rocamora, Marc Julia, Jaime Notario, Lourdes Rodriguez Fernandez-Freire, Antonio Sahuquillo-Torralba, David Vidal, Raquel Rivera, Gregorio Carretero, Almudena Mateu, Pablo de la Cueva, Jose Manuel Carrascosa

Summary: This study aimed to assess the effectiveness and safety of guselkumab in the treatment of moderate to severe plaque psoriasis in routine clinical practice. The results showed that guselkumab had significant efficacy and good safety profile at 24 weeks.

DERMATOLOGIC THERAPY (2022)

Article Biochemistry & Molecular Biology

VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures

Amalia Lamana, David Castro-Vazquez, Hortensia de la Fuente, Ana Triguero-Martinez, Rebeca Martinez-Hernandez, Marcelino Revenga, Raul Villanueva-Romero, Mar Llamas-Velasco, Pablo Chicharro, Yasmina Juarranz, Monica Marazuela, Marco Sales-Sanz, Rosario Garcia-Vicuna, Eva Tomero, Isidoro Gonzalez-Alvaro, Carmen Martinez, Rosa P. Gomariz

Summary: This study investigated the expression of vasoactive intestinal peptide (VIP) and its receptors in immune-mediated inflammatory disorders (IMID), and identified miRNA signatures associated with their expression. The results suggest that the expression of VIP/VPAC2 may serve as markers for IMID and provide insights into the role of the VIP/VPAC axis and miRNA signatures in immune-mediated diseases.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Letter Dermatology

Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice

A. Reymundo, E. Vilarrasa, O. Baniandres, L. Rodriguez-Fernandez-Freire, R. Feltes, M. Llamas-Velasco, E. Dauden

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Article Dermatology

Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

Pablo Chicharro, Mar Llamas-Velasco, Susana Armesto, Enrique Herrera Acosta, David Vidal, Eva Vilarrasa, Raquel Rivera-Diaz, Pablo De-la-Cueva, Antonio Martorell-Calatayud, Ferran Ballesca, Isabel Belinchon, Gregorio Carretero, Lourdes Rodriguez, Alberto Romero-Mate, Josep Pujol-Montcusi, Laura Salgado, Antonio Sahuquillo-Torralba, Pablo Coto-Segura, Ofelia Baniandres Rodriguez, Rosa Feltes, Jose Riera-Monroig, Esteban Dauden

Summary: The study assessed the long-term effectiveness and safety of secukinumab in Spanish patients with moderate-to-severe psoriasis in a daily practice setting, finding that the drug was particularly effective for patients with high PSI and had good long-term safety in routine clinical practice.

DERMATOLOGIC THERAPY (2022)

Article Dermatology

Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group

Vicenc Rocamora, Laura Crespi, Marta Ferran, Mar Llamas-Velasco, Elena del Alcazar, Jose M. Carrascosa, Emma Beltran, Ana Urruticoechea-Arana, Jose Luis Lopez Estebaranz, David Vidal, Josep Riera, Lourdes Rodriguez, Susana Armesto, Josep M. Fernandez, Gloria Aparicio, Silvia Perez, Saray Porcar, Encarna Montesinos, Fernando Gallardo

Summary: This study evaluated the effectiveness and tolerability of Guselkumab in the treatment of psoriatic arthritis in clinical practice. The results showed that Guselkumab effectively controlled both joint and skin manifestations. No new safety concerns were found, and the majority of patients continued the treatment after 2 years of follow-up.

DERMATOLOGIC THERAPY (2022)

Article Health Care Sciences & Services

CNVs Associated with Different Clinical Phenotypes of Psoriasis and Anti-TNF-Induced Palmoplantar Pustulosis

Alejandra Reolid, Antonio Sahuquillo-Torralba, Ancor Sanz-Garcia, Rafael Botella-Estrada, Ester Munoz-Aceituno, Mar Llamas-Velasco, Jorge Garcia-Martinez, Esteban Dauden, Francisco Abad-Santos, Maria C. Ovejero-Benito

Summary: This study aims to identify DNA copy number variations (CNVs) associated with different clinical phenotypes of psoriasis, and to explore the genetic background of anti-TNF-induced palmoplantar pustulosis (PPP). The results suggest that certain genes may play a role in the development of anti-TNF-induced PPP.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Editorial Material Dermatology

Coexistence of psoriasiform stratum corneum and underlying lichenoid features in skin biopsies of cutaneous reactions to anti-PD1

B. Butron-Bris, I. Llado, L. Martos-Cabrera, R. Sampedro, J. Fraga, P. Rodriguez-Jimenez, M. Llamas-Velasco

JOURNAL OF CUTANEOUS PATHOLOGY (2023)

Article Dermatology

Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice

Antonio Costanzo, Mar Llamas-Velasco, Gabriella Fabbrocini, Aldo Cuccia, Raquel Rivera-Diaz, Kristian Gaarn Du Jardin, Ismail Kasujee, Lluis Puig, Jose Manuel Carrascosa

Summary: The TRIBUTE study assessed the efficacy and impact on health-related quality of life of Tildrakizumab in moderate-to-severe psoriasis patients in conditions similar to clinical practice. After 24 weeks, a high proportion of patients achieved significant improvement in psoriasis signs and quality of life. Patient-reported outcomes showed improvements in sleep outcomes, work productivity, and treatment satisfaction. The safety profile was favorable.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Oncology

A 3-dimensional histology computer model of malignant melanoma and its implications for digital pathology

Alexander Kurz, Dieter Krahl, Heinz Kutzner, Raymond Barnhill, Antonio Perasole, Maria Teresa Fernandez Figueras, Gerardo Ferrara, Stephan A. Braun, Hans Starz, Mar Llamas-Velasco, Jochen Sven Utikal, Stefan Froehling, Christof von Kalle, Jakob Nikolas Kather, Lucas Schneider, Titus J. Brinker

Summary: This study developed the first human 3D melanoma histology model with complete data and code availability. Through testing and discussion, it is found that 3D histology models have potential applications in digital pathology, but there are still limitations that need to be addressed.

EUROPEAN JOURNAL OF CANCER (2023)

Article Dermatology

Metachronous primary secretory carcinomas of the eyelid and the parotid gland

M. Llamas-Velasco, K. Kiss, L. Melchior, T. Mentzel

JOURNAL OF CUTANEOUS PATHOLOGY (2023)

Letter Dermatology

Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice

A. Reymundo, S. Armesto, L. Rodriguez, O. Baniandres, A. Sahuquillo-Torralba, T. Torres, P. de la Cueva, M. Llamas-Velasco, E. Dauden

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Letter Dermatology

Super-responders in psoriasis under interleukin 23 inhibitor treatments, experience in two centres

M. Menendez Sanchez, A. Muniz de Lucas, E. Perez Fernandez, M. Llamas Velasco, D. P. Ruiz Genao, J. L. Lopez Estebaranz

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

No Data Available